AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB ...
Amgen presents new data on IMDELLTRA (tarlatamab-dlle) at 2024 WCLC, showing potential for combination with PD-L1 inhibitor as first-line maintenance therapy in ES-SCLC and sustained safety and efficacy in previously treated ES-SCLC.
Related Clinical Trials
Reference News
Amgen presents new data on IMDELLTRA™ (tarlatamab-dlle), a DLL3-targeting BiTE® molecule, at the 2024 WCLC, highlighting its efficacy in extensive-stage small cell lung cancer (ES-SCLC) as both a monotherapy and in combination with PD-L1 inhibitors.
Extended follow-up of DeLLphi-300 trial shows tarlatamab, a bispecific T-cell engager, benefits previously treated small cell lung cancer patients with 25.0% objective response rate, 11.2 months median duration of response, and 17.5 months median overall survival. At recommended 10 mg every 2 weeks, 35.3% response rate, 14.9 months median duration, 20.3 months median survival, and 29.4% sustained disease control at ≥ 52 weeks. Intracranial activity observed in 62.5% with baseline CNS lesions ≥ 10 mm.
Amgen presents new data on IMDELLTRA (tarlatamab-dlle) at 2024 WCLC, showing potential for combination with PD-L1 inhibitor as first-line maintenance therapy in ES-SCLC and sustained safety and efficacy in previously treated ES-SCLC.
Tarlatamab-dlle (Imdelltra; Amgen) demonstrated a manageable safety profile, sustained disease control, and positive survival outcomes in patients with first-line maintenance extensive-stage small cell lung cancer (ES-SCLC) at the World Conference on Lung Cancer 2024. The drug, a bispecific T cell engager, showed a median overall survival of 15.2 months and an objective response rate of 40% in phase 2 of the DeLLphi-303 study. Tarlatamab-dlle received accelerated FDA approval earlier this year for ES-SCLC that has progressed after platinum-based chemotherapy, with a median overall survival of 14.3 months and a median duration of response of 9.7 months.